Alpha-Antitrypsin Deficiency Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies- Grifols, Shire, Kamada, CSL Behring, LFB Biotechnologies, Alnylam, Dicerna, and Others

Delveinsight Business Research LLP
DelveInsight’s “Alpha-Antitrypsin Deficiency Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Alpha-Antitrypsin Deficiency Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Alpha-Antitrypsin Deficiency market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Alpha-Antitrypsin Deficiency: An Overview

Alpha Antitrypsin Deficiency is the most common hereditary disorder in which the body is unable to produce a sufficient amount of Alpha-Antitrypsin (AAT) protein. Alpha-Antitrypsin (AAT) protein plays an important role in protecting organs of the body such as the liver and lungs from the harmful effects of proteolytic enzymes such as neutrophil elastase. Thus, AATD leads to an increased risk of developing a liver disease like Cirrhosis, as well as lung diseases such as Emphysema Chronic Obstructive Pulmonary Disease (COPD), and Panniculitis.

Alpha-Antitrypsin Deficiency Market Key Facts

As per DelveInsight estimates, the total Alpha- Antitrypsin Deficiency (AATD) prevalent population in 6 major markets (i.e the United States and EU5 (the United Kingdom, Germany, Italy, France, and Spain) was found to be 1,835,600+ in 2017

Among the EU5 countries, Germany has the highest prevalent population of AATD with 34,300+ cases, followed by the United Kingdom.

Men and women are equally affected by Alpha Antitrypsin Deficiency. 

DelveInsight Analysts have observed the population with the PISS allele to have the highest numbers, followed by PISZ. However, the most prevalent type of deficient allele associated with AAT Deficiency is the Z allele.

Alpha-Antitrypsin Deficiency Market

The Alpha- Antitrypsin Deficiency (AATD) market size is expected to increase during the study period owing to the launch of upcoming therapies.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Alpha-Antitrypsin Deficiency market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Alpha-Antitrypsin Deficiency market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Alpha-Antitrypsin Deficiency Epidemiology

The epidemiology section covers insights about the historical and current Alpha-Antitrypsin Deficiency patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Alpha- Antitrypsin Deficiency (AATD) Epidemiology Subtype Segmentation –

Prevalent Population of Alpha Antitrypsin Deficiency

Diagnosed Prevalent Population of Alpha Antitrypsin Deficiency

Gender-Specific Prevalent Population of Alpha Antitrypsin Deficiency

Population at risk of Alpha Antitrypsin Deficiency

Comorbidities associated with Alpha Antitrypsin Deficiency

Alpha-Antitrypsin Deficiency Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alpha-Antitrypsin Deficiency market or expected to get launched in the market during the study period. The analysis covers Alpha-Antitrypsin Deficiency market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Alpha-Antitrypsin Deficiency Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Get the PDF Sample of the Report:-

Alpha-Antitrypsin Deficiency Therapeutics Analysis

Some of the key companies in the Alpha- Antitrypsin Deficiency (AATD) Market include- 




CSL Behring

LFB Biotechnologies

Alnylam Pharmaceuticals

Dicerna Pharmaceuticals 

Arrow Head Pharmaceuticals and many others.

Alpha- Antitrypsin Deficiency (AATD) Therapies covered in the report include:




VX-814 & VX-864

Inhaled AAT (also known as Inhaled Alpha-1 Antitrypsin)

And many more.

Get More Detailed Insights into the Emerging Therapies & Key Companies:-

Table of Content

1. Key Insights

2. Executive Summary 

3. Alpha-Antitrypsin Deficiency Competitive Intelligence Analysis

4. Alpha-Antitrypsin Deficiency Market Overview at a Glance

5. Alpha-Antitrypsin Deficiency Disease Background and Overview

6. Alpha-Antitrypsin Deficiency Patient Journey

7. Alpha-Antitrypsin Deficiency Epidemiology and Patient Population

8. Alpha-Antitrypsin Deficiency Treatment Algorithm, Current Treatment, and Medical Practices

9. Alpha-Antitrypsin Deficiency Unmet Needs

10. Key Endpoints of Alpha-Antitrypsin Deficiency Treatment

11. Alpha-Antitrypsin Deficiency Marketed Products

12. Alpha-Antitrypsin Deficiency Emerging Therapies

13. Alpha-Antitrypsin Deficiency Seven Major Market Analysis

14. Attribute Analysis

15. Alpha-Antitrypsin Deficiency Market Outlook (7 major markets)

16. Alpha-Antitrypsin Deficiency Access and Reimbursement Overview

17. KOL Views on the Alpha-Antitrypsin Deficiency Market.

18. Alpha-Antitrypsin Deficiency Market Drivers

19. Alpha-Antitrypsin Deficiency Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:-

Other Latest Reports By DelveInsight

Asthma Diagnostic Devices Market

DelveInsight’s “Asthma Diagnostic Devices Market” report delivers an in-depth understanding of Asthma Diagnostic Devices, the historical and forecasted Asthma Diagnostic Devices market size, share, trends in North America, Europe, APAC, and RoW,  as well as the emerging devices and key companies operating in the domain.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States